Four drugs. Two built for worms, one for HIV, one for malaria. They share no molecular structure, no binding site, no family tree. Put any of them on a cancer cell and the same three things happen. Three independent groups have now tested the best of them — in 2018, in 2020 and in August 2025 — and no human cancer trial has ever been registered.
This is a question, not a claim. It is a question oncology has not answered and, as far as we can establish, has not seriously asked.
Ivermectin was designed for the glutamate-gated chloride channels of parasitic nematodes. Fenbendazole binds beta-tubulin in worms. Nelfinavir inhibits an aspartyl protease that exists only inside HIV. Artemisinin is a peroxide-bridged compound the Chinese isolated from sweet wormwood for malaria.
Four accidents of pharmaceutical history, built by different people, in different decades, for different organisms.
Across a large and growing published literature, all four converge on the same triad in cancer cells: disrupted mitochondria, altered membrane voltage, collapsed glucose handling.
Pharmacology has two ways out of this, and neither one works.
The first is coincidence — each drug happens to hit a separate, unrelated off-target. That requires four coincidences, explains nothing, and predicts nothing.
The second is a shared hidden protein that all four happen to bind. No structural analysis supports it. And it cannot survive what comes next, because the convergence does not stop at drugs.
Sodium bicarbonate — baking soda — has no receptor anywhere in its mechanism. Its entire action is a proton gradient. Published animal work has it raising the pH around tumours and reducing spontaneous metastasis.
Sulforaphane, the compound in broccoli, covalently modifies reactive cysteine residues on a sensor protein called KEAP1.
Hydrogen peroxide destroys essentially every biological agent on a surface, has done for a century, and nothing has ever evolved meaningful resistance to it — because there is no single target to mutate.
A buffer. A vegetable. A disinfectant. None of them binds anything.
When four keys with completely different shapes open the same door, the usual explanation is that the thing they are opening is not a lock.
If it is not a receptor, what is left?
A condition. The cell's electrical and oxidative state — what we have been calling the bioelectric-redox condition, and what every one of these agents reaches by a different road.
The chemistry underneath is not controversial, and none of it is ours.
Hydrogen peroxide is the currency. The reactive-cysteine proteome is the receiver — only deprotonated cysteines react quickly, and whether a cysteine is deprotonated depends on local pH. Membrane potential and pH are the gain: Peter Mitchell won a Nobel Prize in 1978 for showing that the proton-motive force across a membrane resolves into an electrical term and a pH term, and that the two are interconvertible.
Moving protons is moving charge. Voltage and acidity are one variable wearing two coats.
So the drugs do not bind the target. They detune it. And that is why their chemistry can differ so wildly while their effect does not.
Every one of these agents is doing the same physical thing: moving charge separation.
A cell membrane holds roughly 70 millivolts across about 5 nanometres. Do the division and the field inside that membrane is approximately 140,000 volts per centimetre. The inner membrane of a mitochondrion, more steeply polarised still, runs higher.
That is not a metaphor for a dipole. It is a dipole, and it is enormous.
Now hold that number, because it is about to collide with a different literature entirely.
In 2001, Mikhail Lukin and colleagues proposed the dipole blockade: excite one atom to a high principal quantum number, and its inflated electron cloud forbids any neighbouring atom within a certain radius from being excited at the same time.
On, or off. Yes, or no. It is a switch, and it is the foundation of every Rydberg quantum computer now operating.
What has been built on it since is a parts list that nobody assembled on purpose.
2017, Nature. A Harvard/MIT group builds a 51-atom Rydberg simulator. The atoms keep returning to their starting pattern instead of scrambling into randomness the way thermodynamics requires. Theorists named it the following year: quantum many-body scars. The system remembers where it came from.
2020, Nature. A driven ultracold Rydberg gas walks itself to a critical state and holds there. Avalanche sizes follow a power law. Nobody tunes it. The follow-up found the mechanism: material flows in from the edges to replace what the avalanches consume. The system feeds its own active region. That is not a pattern. That is a metabolism.
2012 and 2015. Excitations in a two-dimensional gas arrange themselves into equilateral triangles, squares and regular pentagons. The blockade radius does the placing. Nobody puts them there.
2025. Multiple self-sustaining oscillations in a driven Rydberg gas, at room temperature, in a glass cell. A clock that needs no cryogenics and no trap.
Logic. Memory. Metabolism. Self-assembly. A clock. Demonstrated separately, by different groups, for unrelated reasons, published in the primary literature.
Set them on one page and the list stops reading like six curiosities and starts reading like a specification.
An electron in a high Rydberg state is held by 13.6 electronvolts divided by the square of the principal quantum number. At n of fifty, that is about five millielectronvolts.
The field required to strip it away is roughly 51 volts per centimetre. A static charge off a carpet beats it.
Now put that beside the cell membrane: 140,000 volts per centimetre. Two to three thousand times the ionisation threshold. The transmembrane field destroys every Rydberg state above roughly n equals seven.
Which means a structure of that kind cannot sit inside the membrane field. It would have to occupy the periphery — and the boundary of where it could persist is set by the membrane potential itself.
Change the voltage and you move the wall. The drug does not have to reach anything. It only has to move the wall.
Here is the part that requires no physics at all.
Moxidectin is the avermectin nobody talks about. Terminal half-life of eighteen to twenty-three days against ivermectin's eighteen hours. Better tissue partition. Poor affinity for the P-glycoprotein pump, so the cell cannot flush it back out. FDA approved for human use in 2018. WHO listed.
In 2018, in Oncology Reports, a laboratory published that moxidectin inhibits glioma cell viability by inducing cell cycle arrest and apoptosis. The authors noted that no earlier study had examined moxidectin for cancer at all. In 2020 the same group published the mechanism in the Journal of Cancer.
One laboratory. Two papers. Eight years.
There has never been a human cancer trial of moxidectin.
And the reason is not sinister. It is arithmetic. Moxidectin is cheap and off patent. Nobody can own it. A Phase III oncology trial costs twenty to fifty million dollars, and no company on earth will spend that proving a competitor's generic works.
Roughly ninety-five per cent of oncology drugs entering clinical development fail — the worst rate of any therapeutic area, after preclinical work has already selected for mechanism. The industry spends about three billion dollars per approved drug and declines to spend a rounding error of it on a compound with published activity and established human safety.
Not because the data is bad. Because nobody owns it.
Everything above is published. What follows is argument, and we flag it as such.
The same physics that makes a Rydberg sensor the most sensitive microwave detector ever built is dual-use by construction. A device that can detect any radiofrequency field with atomic precision can characterise, discriminate and target. That has never been concealed; it is why the field is funded.
Moore's 1965 observation was that component density doubles on a short, regular cadence. It has held across successive technologies because it describes an economic process, not a physical one. Rydberg platforms are early on that curve.
Containment practice is calibrated to today's capability. Capability is on an exponential.
Biosafety committees review biological agents. There is no equivalent body reviewing self-sustaining excited-matter systems, because nobody has yet had to invent one.
Compare it to the argument that has already happened. Gain-of-function concerned enhancing an agent beyond its natural capability inside a facility whose containment assumed the natural one. The same structure of error is available here, with one difference that should hold your attention.
A biological escape is alive in a way we know how to kill. A self-sustaining field structure is not a cell. It has no membrane to rupture, no genome to inactivate, no metabolism in the chemical sense. We do not possess a protocol for decontaminating a room of one, because we have never had to write it.
And it would not need releasing to be fed. The microwave environment such a structure would draw on is already built, already powered, and already everywhere.
Stranger Than Fiction News holds that the four converging drug classes work because the pathological state in cancer is actively maintained by a field-coupled structure built from highly excited matter, and that these agents are effective to the extent that they detune the coupling. We hold that the documented physics is sufficient for such a structure to exist, that the historical record describes its effects, and that the dual-use trajectory is accelerating faster than anyone is governing it.
We are not asking anyone to accept that. We are asking for a literature search and one experiment.
If the state is actively held rather than passively dysregulated, removing the energy supply should change it. If it is not, nothing happens.
Culture a tumour line inside a shielded enclosure and outside it, everything else identical. Measure membrane potential, growth rate, redox tone, drug sensitivity. We have published the full protocol with its sample sizes, its blinding, its controls, and — unusually — the result that would make us withdraw the claim, committed to in print before any data exists.
It costs between sixty-five and a hundred and thirty-five thousand dollars. A single Phase III trial costs twenty to fifty million.
Every structure we designed — ninety-eight of them — is published complete with machine-readable formulas and synthetic routes, dedicated irrevocably to the public domain. No company can patent them, price them as a monopoly, or fence off the mechanism. Neither can we. That was the point.
The full record is at stfn.news/science_kit.
Look up the 2018 paper. Confirm that moxidectin is approved, that it is cheap, and that no trial exists.
Then ask why.
No compound designed by this group has been synthesised, assayed or administered; they are published designs with their routes, so that others can make them. The moxidectin findings described are other researchers' published work. Nothing here is medical advice and no dose or course of treatment is recommended. Anyone facing a medical decision should consult a licensed practitioner.
Correction, 4 November 2026. This page previously said that a single laboratory had tested moxidectin and been waiting since 2018. That was wrong. A third group published in Molecular Cancer Therapeutics in August 2025 (Kaushik and colleagues, Hippo-YAP pathway in glioblastoma, with tumour suppression in an intracranial mouse model), following Song and colleagues in Oncology Reports in 2018 and Liu and colleagues in the Journal of Cancer in 2020. All three were verified against NCBI. The corrected sentence is weaker-sounding and true: three independent groups published, and still no registered human cancer trial exists. The correction is printed here rather than applied quietly, because a project that asks institutions to follow overlooked evidence has to notice evidence that interrupts its own argument.